Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the CF therapeutic landscape through a strategic licensing agreement with AbbVie. Announced on July 16, the partnership allows Sionna to develop and commercialize multiple clinical-stage CF compounds from AbbVie, including two Phase II compounds (ABBV-2222 and ABBV-3067) and a Phase I compound (ABBV-2851), marking a substantial expansion of its pipeline. AbbVie will receive an undisclosed upfront payment, equity investment in Sionna, and late-stage development and commercial milestones and royalties.